^
    Apply
    Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer (NCT05410821)
    Phase 2
    The First Affiliated Hospital of Xiamen University
    Recruiting
    Last update posted :
    08/04/2022
    Initiation :
    06/15/2022
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    FAP
    |
    177Lu-DOTA-EB-FAPI • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer (NCT05453799)
    Phase 2
    Northwestern University
    Not yet recruiting
    Last update posted :
    07/12/2022
    Initiation :
    07/22/2022
    Primary completion :
    07/15/2024
    Completion :
    07/15/2024
    BRAF • CD4
    |
    BRAF V600E
    |
    vudalimab (XmAb717)
    Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)
    Phase N/A
    Leiden University Medical Center
    Recruiting
    Last update posted :
    04/11/2022
    Initiation :
    01/10/2022
    Primary completion :
    01/01/2024
    Completion :
    06/01/2024
    TG
    |
    lenvatinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (A091302)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    04/04/2022
    Initiation :
    10/01/2014
    Primary completion :
    01/28/2021
    Completion :
    08/06/2024
    TG
    |
    sorafenib • everolimus
    Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer (NCT02393690)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    03/31/2022
    Initiation :
    05/04/2015
    Primary completion :
    07/17/2020
    Completion :
    12/31/2022
    TG
    |
    Koselugo (selumetinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (NCT02973997)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    01/06/2022
    Initiation :
    02/07/2018
    Primary completion :
    10/08/2022
    Completion :
    09/30/2024
    ALB
    |
    Keytruda (pembrolizumab) • lenvatinib
    The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (NCT04447183)
    Phase 2
    Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    Recruiting
    Last update posted :
    12/01/2021
    Initiation :
    11/23/2020
    Primary completion :
    02/01/2022
    Completion :
    10/01/2022
    TG
    |
    Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • recombinant human thyroid stimulating hormone for injection (rhTSH)
    A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (NCT02702388)
    Phase 2
    Eisai Inc.
    Completed
    Last update posted :
    11/24/2021
    Initiation :
    06/08/2017
    Primary completion :
    12/12/2019
    Completion :
    09/10/2020
    TG
    |
    lenvatinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer (NCT01208051)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/15/2021
    Initiation :
    09/09/2010
    Primary completion :
    02/01/2020
    Completion :
    02/01/2020
    BRAF • RAS • TG
    |
    RAS mutation
    |
    lenalidomide • Recentin (cediranib)
    Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy (NCT04554680)
    Phase 2
    National University Hospital, Singapore
    Recruiting
    Last update posted :
    03/05/2021
    Initiation :
    12/30/2020
    Primary completion :
    12/01/2021
    Completion :
    04/01/2022
    TG
    |
    BRAF V600E • BRAF V600 • RAS mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (NCT03914300)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/26/2021
    Initiation :
    07/15/2019
    Primary completion :
    01/15/2022
    Completion :
    01/15/2022
    ALB
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar)
    Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (NCT01811212)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/03/2018
    Initiation :
    05/08/2013
    Primary completion :
    07/13/2015
    Completion :
    10/09/2017
    BRAF • TG
    |
    Cabometyx (cabozantinib tablet)
    A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours (NCT01736163)
    Phase 4
    Genzyme, a Sanofi Company
    Completed
    Last update posted :
    03/23/2015
    Initiation :
    05/01/2012
    Primary completion :
    08/01/2012
    Completion :
    08/01/2012
    TG
    Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine (NCT00098813)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    05/28/2014
    Initiation :
    10/01/2004
    Primary completion :
    08/01/2009
    Completion :
    08/01/2009
    TG
    |
    Istodax (romidepsin)